SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Bio Technology General - BTGC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bosco who wrote (1884)7/16/1999 9:01:00 AM
From: Michael G. Potter  Read Replies (1) of 2028
 
If you study what happens to a stock when a company announces an acquisition, you will see that the acquiring company's stock usually goes down. This is especially true if cash is used to fund the acquisition. It has to do with the risk (moving cash to another asset) and the premium usually paid in an aquisition.

Now, BTGC may buy a few products that they are better able to distribute, but their strength isn't really in distribution, but in research.

I agree that BTGC has good potential, but nothing past Phase II. They also stuffed the channel in the past for their most profitable drug and that will take time to resolve.

Michael
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News